Which of the following actions should the nurse take to manage increased intracranial pressure (ICP) for a client with a closed-head injury? Select all that apply.

Mechanical ventilation alarms are critical safety features that alert the nurse to changes in airway resistance or lung compliance. A high-pressure alarm indicates increased resistance to airflow, which can be caused by airway obstruction, bronchospasm, secretions, or patient-related factors such as biting the endotracheal tube. Prompt identification of the cause is essential to restore adequate ventilation and prevent hypoxia or barotrauma.

Rationale:
A. Stable respiratory rate per minute as prescribed does not contribute to a high-pressure alarm. A set and stable respiratory rate indicates that the ventilator is functioning as intended and does not reflect increased airway resistance or obstruction. This finding is unrelated to causes of increased airway pressure.

B. Cuff pressure maintained above 30 cm H₂O is not a direct cause of a high-pressure ventilator alarm, although it may increase the risk of tracheal mucosal injury. High-pressure alarms are typically triggered by airway obstruction or reduced lung compliance rather than cuff inflation levels. Normal cuff pressures are maintained to prevent air leaks and aspiration.

C. Excess secretions in the airway can obstruct airflow through the endotracheal tube, increasing resistance and triggering a high-pressure alarm. Secretions narrow the airway lumen, making ventilation more difficult and requiring suctioning to restore patency. This is a common and reversible cause of ventilator alarms.

D. Bronchospasm increases airway resistance due to constriction of bronchial smooth muscles, which reduces airflow and elevates airway pressures. This condition is commonly seen in clients with asthma or reactive airway disease. It requires prompt intervention with bronchodilators to relieve airway obstruction.

E. Biting the endotracheal tube can physically obstruct airflow, leading to increased resistance and activation of the high-pressure alarm. This is often seen in inadequately sedated clients or those emerging from sedation. Use of bite blocks or sedation adjustment may be necessary to prevent recurrence.

Parkinson’s disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the substantia nigra of the brain. This dopamine deficiency leads to motor symptoms such as tremors, rigidity, bradykinesia, and postural instability. Carbidopa-levodopa is the standard pharmacologic treatment used to restore dopamine activity in the central nervous system. It works by increasing dopamine availability in the brain, improving motor function and reducing symptoms.

Rationale:
A. It blocks acetylcholine release in the brain is incorrect because carbidopa-levodopa does not directly inhibit acetylcholine activity. While anticholinergic drugs may be used in Parkinson’s disease to reduce tremors, this medication primarily targets dopamine replacement rather than acetylcholine suppression. Its main mechanism is not based on cholinergic blockade.

B. It enhances the reuptake of dopamine in the synapses is incorrect because carbidopa-levodopa does not work by increasing dopamine reuptake. Dopamine reuptake inhibitors are a different class of medications that prolong dopamine action in the synaptic cleft. Carbidopa-levodopa instead increases the actual synthesis of dopamine in the brain.

C. It increases the production of dopamine in the brain is correct because levodopa is a precursor that crosses the blood-brain barrier and is converted into dopamine in the central nervous system. Carbidopa prevents peripheral breakdown of levodopa, allowing more of it to reach the brain. This results in increased dopamine levels, improving motor control and reducing Parkinsonian symptoms.

D. It inhibits the breakdown of serotonin in the brain is incorrect because carbidopa-levodopa does not affect serotonin metabolism. Serotonin reuptake inhibition or breakdown prevention is associated with antidepressant medications, not antiparkinsonian therapy. The drug’s primary action is specifically related to dopamine synthesis rather than serotonin regulation.